RxDoctor Payments Data

Jennifer Barbieri, MD

Pulmonary Disease · Rome, GANPI 1902849110

Payments from drug & device makers

$8,509in general payments, 2019–2025

Across 460 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Boehringer Ingelheim$1K
  • Actelion Pharmaceuticals US, Inc.$577
  • AstraZeneca$484
  • Mylan Specialty L.p.$467
  • United Therapeutics Corporation$410
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$8,44099%
  • Education$691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,509 in reported general payments places this provider in the 60th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$171,472
Medicare patients
524
Services billed
1,967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter811$631,820
OfevNintedanib Esylate27$320,206
XolairOmalizumab48$257,332
Prolastin CAlpha-1-Proteinase Inhibitor14$146,400
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr247$130,340
TezspireTezepelumab-Ekko28$122,660
Breo ElliptaFluticasone/Vilanterol234$110,273
Spiriva RespimatTiotropium Bromide120$81,590
Stiolto RespimatTiotropium Br/Olodaterol Hcl73$52,752
NucalaMepolizumab13$47,955
Dupixent SyringeDupilumab12$46,665
Combivent RespimatIpratropium/Albuterol Sulfate56$41,581
Spiriva HandihalerTiotropium Bromide39$36,898
Advair HfaFluticasone Propion/Salmeterol73$36,297
SymbicortBudesonide/Formoterol Fumarate92$31,141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta$1,572$969,0781,445 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$1,226$496,129276 claims
AstraZenecaTezspire, Symbicort, Breztri Aerosphere$484$182,980167 claims
Grifols USA, LLCProlastin C$400$146,40014 claims
PfizerEliquis$67$13,10015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →